Opinion | Published:

The NIH translational research center might trade public risk for private reward

Nature Medicine volume 17, page 1176 (2011) | Download Citation

The new National Center for Advancing Translational Sciences planned for the US National Institutes of Health intends to help transform biological findings into new therapeutic products. But if taxpayer funding of risky biomedical research translates into lucrative new medicines, the public should share in the economic benefits as well.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Nat. Rev. Drug Discov. 10, 14 (2011).

  2. 2.

    , et al. N. Engl. J. Med. 364, 535–541 (2011).

  3. 3.

    27 Apr 2011. The NIH National Center for Advancing Translational Sciences: How Will It Work? <> (2011; last accessed 16 Sept 2011).

Download references

Author information

Affiliations

  1. Jerry Avorn is a professor of medicine and Aaron S. Kesselheim is an assistant professor of medicine at Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA.

    • Jerry Avorn
    •  & Aaron S Kesselheim

Authors

  1. Search for Jerry Avorn in:

  2. Search for Aaron S Kesselheim in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm1011-1176

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing